Tarsus Pharmaceuticals, Inc. — Form 8-K
Filed July 13, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 32/100
What the filing says
Form 8-K filed July 13, 2026 discloses Item 5.02 event concerning departure of directors/officers or appointment of officers and/or compensatory arrangements. The specific names, titles, dollar amounts, effective dates, and details of any changes are not provided in the filing header or accessible document excerpts.
Why this rating
Leadership/compensation changes are routine disclosures absent specific material details (severance, equity impact, or strategic loss). Cannot assess materiality without concrete terms.
Extracted items
See more from July 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.